iShares Neuroscience and Healthcare ETF IBRN

Medalist Rating as of | See iShares Investment Hub

Morningstar’s Analysis IBRN

Will IBRN outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A sound investment process and strong management team underpin iShares Neuroscience and Healthcare ETF's Morningstar Medalist Rating of Gold.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings IBRN

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 41.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Biohaven Ltd

5.08 190,540
Healthcare

PTC Therapeutics Inc

4.41 165,470
Healthcare

Alkermes PLC

4.14 155,394
Healthcare

Dyne Therapeutics Inc Ordinary Shares

4.06 152,353
Healthcare

Xenon Pharmaceuticals Inc

4.05 151,950
Healthcare

Catalyst Pharmaceuticals Inc

3.94 147,667
Healthcare

SK Biopharmaceuticals Co Ltd Ordinary Shares

3.92 146,810
Healthcare

argenx SE ADR

3.90 146,124
Healthcare

Axonics Inc

3.90 146,039
Healthcare

Intra-Cellular Therapies Inc

3.82 143,048
Healthcare

Sponsor Center